Contakt World Announces DTC Eligibility and OTC Pink Listing

Contakt World Announces DTC Eligibility and OTC Pink Listing

Contakt World Technologies Corp. (CSE: HELP) (OTC Pink: TLOOF) (FSE: B2I0) (the "Company", "Contakt" or "Contakt World"), a SaaS company committed to delivering a diverse suite of subscription based software solutions for healthcare and other industries, is pleased to announce that its CUSIP 20177G108 is now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States. Its common shares have commenced trading on the OTC Pink Market in the USA under the symbol "TLOOF" (the "Listing"). The Company's common shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol "HELP." The Company expects the Listing to provide greater exposure, visibility and trading convenience for U.S. investors, resulting in enhanced liquidity and extended reach.

Other Recent Related News from Contakt World:

Contakt World Launches Sales Representative Program to Continue to Grow Revenue for Its Cash Flow Positive HealthCheck Screening Tool and Vaccine Passport Solution

Contakt World to Offer Vaccine Passport and Verification Platform to Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

Contakt World Announces Acquisition of HealthCheck, a SaaS Health Screening App for Students, Customers, Employees, and Visitors

To Learn More:

If you are an organization seeking daily health screening and vaccine passports, vaccine wallets, or vaccine credentials, schedule a demo by visiting https://www.stratumhealth.io/. Our team will work with your organization to define the product that better suits your needs.

About Contakt World

Contakt World's mission is to develop or acquire and deliver software as a service (SaaS) that improves access to, efficiencies within, and quality of healthcare and other industries in all its forms. Contakt World's portfolio presently includes HealthCheck by Stratum which is used in over 1,000 locations, and Portum Pass https://contakt.world/portum/. Contakt World is actively looking to broaden its software portfolio through acquisitions, partnerships, and joint ventures. The Company is currently looking to broaden its industry scope, looking beyond healthcare, to other industries that can benefit from its current and future solutions.

Sign up for investor updates from Contakt World including updates in the field of vaccine passports and symptom screening by visiting https://contakt.world/help.

Contakt World Contact
Zayn Kalyan
Interim CEO and Director
Direct: 778-938-3367

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Forward-Looking Statements Disclaimer

This press release contains "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"). Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "projects", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements, including statements respecting: the Listing providing greater exposure, visibility and trading convenience for U.S. investors, resulting in enhanced liquidity and extended reach. Although forward-looking statements contained in this press release are based upon what management of Contakt World believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. Contakt World undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/111927

News Provided by Newsfile via QuoteMedia

HELP:CNX
The Conversation (0)
Contakt World - Corporate Update

Contakt World - Corporate Update

  • Demand for HealthCheck, Contakt's marquee solution, continues to grow in the face of the Omicron variant-driven wave of COVID-19 and increasing vaccine mandates and requirements in numerous jurisdictions
  • HealthCheck has added over 20 new customers and has renewed over 130 customer subscriptions within the past 3 months, with nearly 800 customers in total, servicing over 100,000 users in the US alone
  • HealthCheck alone generated nearly $1.35 million CAD in revenue in calendar 2021 (figures unaudited)
  • HealthCheck 3.0 has been officially released, adding vaccine passport, COVID-19 test tracking capabilities, and several improvements to its population management dashboard.
  • Contakt is looking to broaden its portfolio entering 2022, looking to acquire and partner with other SaaS companies in the healthcare sector and beyond

Contakt World Technologies Corp. (CSE: HELP) (OTC Pink: TLOOF) (FSE: B2I0) (the "Company", "Contakt" or "Contakt World"), a SaaS company committed to delivering a diverse suite of subscription based software solutions for healthcare and other industries, is pleased to provide a general corporate update for its shareholders.

HealthCheck
Contakt's COVID Compliance Solution, Stratum Health ("HealthCheck"), has seen significant growth in new customers and renewals over the past 90 days, primarily driven by the recent surge of COVID-19 Omicron variant globally. HealthCheck has added nearly 20 new enterprise clients since October, and new sales continue to growth month over month. Many of HealthCheck's largest clients, including Atlanta County Public Schools, with close to 50,000 users (students and school staff), have extended or renewed their annual contracts, continuing to drive revenue.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Contakt World Provides Company Update as it Continues to Expand its Portfolio of SaaS Solutions and Commercial Presence in the US Market

Contakt World Provides Company Update as it Continues to Expand its Portfolio of SaaS Solutions and Commercial Presence in the US Market

Contakt World is well-positioned to continue to take a leading role as a provider of SaaS solutions designed to meet Federal Vaccine Mandates imposed by the United States

  • A vaccine mandate was recently enacted in the United States for all Federal employees
  • The private sector is following suit, creating demand for Contakt World's portfolio
  • Health Check and Portum's app offers the public and private sector a unique, integrated solution

Contakt World Technologies Corp. (CSE: HELP) (OTC Pink: TLOOF) (FSE: B2I0) (the "Company", "Contakt" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges such as symptom screening and vaccine passports, is pleased to provide a summary of the Company's recent achievements, current operations, and strategic initiatives.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
portum

Contakt World Expands Commercial Portfolio Through Partnership Agreement with Portum for Health Screening, Vaccine Wallet, Vaccine Passport, and More

Contakt World to offer Portum to create safe spaces, healthy places, and peace of mind for all with its digital health pass and vaccine wallet for consumers, businesses, and government

  • A vaccine mandate was recently enacted in the United States for all Federal employees
  • The private sector is following suit, creating demand for Contakt World's portfolio
  • Portum's app offers the public and private sector a unique, integrated solution
  • Contakt World intends to offer the Portum solutions to new and existing customers

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges such as symptom screening and vaccine passports, today announced it has executed a strategic partnership agreement with Portum System LLC ("Portum").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
1000 usd to cad

Contakt World Launches Sales Representative Program to Continue to Grow Revenue for Its Cash Flow Positive HealthCheck Screening Tool and Vaccine Passport Solution

Independent sales representatives provide scalable technology sales opportunity for health screening and vaccine passports to Contakt World and its portfolio companies

  • HealthCheck's existing 1,000+ customer sites were acquired through sales efforts of one part-time independent sales representative and two founders leading to $1.55M CAD revenue and $555K CAD net profit for the twelve-months ended July 31, 20211
  • In addition to plans to bolster its revenue opportunities with vaccine passports and validation, Contakt World just launched a program to aggressively add independent sales representatives to scale sales within employer establishments, K-12 schools and event venues in the US
  • Contakt World's advertisements and initial screening process to add independent sales representatives for health screening, vaccine passports, and future solutions yielded dozens of qualified applicants in less than two weeks
  • Independent sales representatives are expected to grow customer base and increase revenue for HealthCheck and future solutions like vaccine passports on a commission-only basis

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges like symptom screening and vaccine passports, today announced it will create a network of independent sales representatives to scale sales for the recently acquired HealthCheck app, vaccine passports, and future acquisitions or partnering products.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Contakt World to Offer Vaccine Passport and Verification Platform To Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

Contakt World to Offer Vaccine Passport and Verification Platform To Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

HealthCheck app provides an ideal technology environment for combined symptom screening, vaccine passport and verification

  • Contakt World intends to offer existing and new customers integrated tools for vaccine passport and verification.
  • Vaccine passport verification is critical to combat increased fraud  and reduce liability – Contakt World to deliver passport verification solution to ensure accuracy and prevent use of fraudulent vaccine records.
  • Contakt World recently acquired cash flow positive HealthCheck - a health screening tool to assess COVID-19 symptoms quickly and easily via the HealthCheck app - featuring 1,000+ locations in use.
  • News that the Pfizer BioNTech vaccine loses efficacy faster against Delta variant1 suggests a recurring need for boosters, vaccine passports, and health screening for years to come.

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges, today announced it will leverage the recently acquired HealthCheck app to help combat fraud in vaccine credentials and enable privacy-preserving vaccine passports.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
RETRANSMISSION: Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

RETRANSMISSION: Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to announce that it has more than doubled the acreage on the recently acquired George Lake South Antimony Project in New Brunswick, Canada. This project now consists of 4,722 contiguous acres prospective for antimony.

James Nelson, President of Spearmint stated, "In light of the recent ban of antimony by China to the USA, we made this strategic acquisition increasing the size of the George Lake South Antimony Project. Management feels that antimony will be one of the most sought after resources in 2025 and we plan to pursue this space with vigor and are currently evaluating additional projects. Management is formulating a plan on the George Lake South Antimony Project, and management also intends to update the market on Spearmint's crypto diversification plan in the near future as well. These are truly exciting times for Spearmint and Spearmint shareholders."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Elon Musk.

Tech 5: Musk Faces SEC Clash, Broadcom Surges, Google Makes Quantum Chip Breakthrough

Tech stocks surged this week as US and Canadian jobs data bolstered interest rate cut expectations.

Broadcom (NASDAQ:AVGO) became the newest member of the trillion-dollar club, crossing the market cap threshold in early trading on Friday (December 13) after a strong earnings forecast caught attention. Meanwhile, its peer NVIDIA (NASDAQ:NVDA) suffered losses as it prepares to face probes in both China and the US.

Meanwhile, Google (NASDAQ:GOOGL) announced a quantum computing milestone, and Tesla (NASDAQ:TSLA) CEO Elon Musk called out the US Securities and Exchange Commission (SEC) over multiple probes into his business dealings.

Keep reading...Show less
SEC website on phone screen.

SEC Reopens Investigation on Neuralink and Musk’s Twitter Deal

The US Securities and Exchange Commission (SEC) has reopened its investigation into Neuralink, Elon Musk’s brain-implant company, alongside a probe into Musk’s acquisition of Twitter, now rebranded as X.

A letter from Musk’s lawyer, Alex Spiro, disclosed the development on Thursday (December 12), raising questions about the ongoing legal disputes between Musk and the SEC, according to a Reuters report.

The letter, addressed to outgoing SEC Chair Gary Gensler, outlines the reopening of the Neuralink investigation and a settlement demand regarding the Twitter takeover, which happened in 2022.

Keep reading...Show less
Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

Spearmint More Than Doubles the Acreage of the George Lake South Antimony Project in New Brunswick, Canada

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to announce that it has more than doubled the acreage on the recently acquired George Lake South Antimony Project in New Brunswick, Canada. This project now consists of 4,722 contiguous acres prospective for antimony.

James Nelson, President of Spearmint, stated, "In light of the recent ban of antimony by China to the USA, we made this strategic acquisition increasing the size of the George Lake South Antimony Project. Management feels that antimony will be one of the most sought after resources in 2025 and we plan to pursue this space with vigor and are currently evaluating additional projects. Management is formulating a plan on the George Lake South Antimony Project, and management also intends to update the market on Spearmint's crypto diversification plan in the near future as well. These are truly exciting times for Spearmint and Spearmint shareholders."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Spearmint Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike

Spearmint Announces Arrangements to Address Mailing Delays Resulting from Canada Post Strike

Spearmint Resources Inc. (CSE: SPMT) (OTC Pink: SPMTF) (FSE: A2AHL5) (the "Company" or "Spearmint") wishes to provide an update to shareholders on the impact of the strike by the Canadian Union of Postal Workers on the Company's ability to comply with its obligations to deliver to shareholders its financial statements and related disclosure and proxy-related materials in respect of the Company's annual general meeting of shareholders (the "Meeting") scheduled to be held at Cozen O'Connor LLP - 550 Burrard Street, Suite 2501, Vancouver, B.C., on Thursday, Dec. 19, 2024, at 10 a.m. PST.

James Nelson, President of Spearmint stated, "We want all of our shareholders to be aware of the current situation as there are many exciting events occurring for Spearmint in the short and medium term."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech's THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy ("THT") which uses the Company's patented, biocompatible gold nanorods ("GNRs") to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company's third preclinical efficacy study was conducted in an immunologically 'cold' colorectal cancer model ("CT26"), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.

In this preliminary study, whereas no mice that were given standard immunotherapy alone showed any response, 100% of mice in the THT treatment group responded to the same immunotherapy with 50% (4 out of 8) of those tumors eliminated within 12 days of treatment, as shown by the green line in Figure 1, below.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×